BioCurex, Inc.(fka BOCX)

[opportunityknocking]

Terry, I have a question about us licensing and our a patent in regards to Recaf. Read this.................
--------------------------------------------------------------------------------

STOCK ALERT

RJV Networks, Inc. (OTC BB: RJNV)
Press Release----Source: RJV Network, Inc.
http://biz.yahoo.com/n/r/rjvn.ob.html

(OTC BB: RJVN) Announces Cancer Treatment Therapy
Advances Using BioCurex RECAF Technology Through A
Licensing Agreement with its BioKinetix (acquisition
underway).

Thursday December 19, 10:00pm ET

http://finance.yahoo.com/q?s=rjvn.ob&d=t
RJV Network, Inc. (OTC BB:RJVN.OB - News), a Nevada
corporation, is in the process of acquiring BioKinetix
Research Inc. BELLEVUE, Wash., and announces further
developments of the combined Company revolutionary cancer
treatment therapy, now just months away from formal market
testing to begin.

BioCurex Inc. announced on December
16th that it has completed a licensing agreement with
BioKinetix (being acquired by OTC BB: RJVN) to use
BioCurex's RECAF technology. The license will allow
BioKinetix to use its InNexus Super Antibody platform
technology to create therapeutic antibodies; then combining
RECAF antibodies with RJVN Super Antibody technology could
give BioKinetix the potential to create both highly potent
therapeutic antibodies, as well as vaccines to immunize
against the RECAF receptor, creating a highly effective
treatment for most cancers as agreed upon by many world
renowned molecular biologists, including Dr. John Todd
of RJVN BioKinetix.

BioCurex, Inc. is a biotechnology company that is
developing products based on patented / proprietary
technology in the areas of cancer diagnosis, tumor imaging
ad therapeutics. The technology identifies a cancer marker
known as RECAF(tm), which is found on malignant cells from
a variety of cancer types but absent in most normal or
benign cells. Detailed information about BioCurex may be
obtained from their website at biocurex.com .

Created over ten years of expensive research and
development, RECAF technology is able to effectively
locate molecules (markers) that are present on active
cancer cells, but not on healthy cells. The combination
of these two technologies gives BioKinetix the potential
to create a series of therapeutic products that may treat
most cancers. The therapeutics to be developed are
monoclonal antibodies that mark growth factor receptor
on cancer tissue. Combining RECAF antibodies with Super
Antibody technology will give BioKinetix the potential
to create both highly potent therapeutic antibodies, as
well as vaccines to immunize against the RECAF receptor.

On behalf of the Board of Directors,

Mr. Edward Velton, President
Contact: For RJV Network, Inc. Grant Young

Company Name----------------RJV Networks, Inc.
Symbol----------------------RJVN
Current Price---------------$0.10
52 Week High----------------$2.10
52 Week Low-----------------$0.10

Target $4 -to- $6 Q3/2003

Investment Highlights

RJVN projects it will be able to treat most cancers with
its combined targeted therapy treatment which is based
upon an astounding discovery by a molecular biologist
at the Univ. of Michigan - The causal link to breast
and most other malignancies and cancers in the protein
Mammastatin.

RJVN has developed a series of cancer treatment therapies
which utilize pan-cancer market antibodies. Antibody
therapies do not create chemical toxicity and, as such,
are fast tracked through the regulatory approval process.
Using this approach, RJVN is targeted to enter testing
for its products in six months.

RJVN's combination of two leading, well known technologies
previously announced by BioCurex and InNexus Corp along
with RJVN's key MAb protein replicating technology has
allowed the Company to create a series of patented
therapeutic products that many molecular biologists
believe will treat most cancers.

RJVN's R&D and Management are led by Dr. John Todd,
Dr. Charles Morgan (a world renowned molecular biologist
and 5 other industry leading Dr's all with several
years experience in bio-tech development.
................................................................................................................................................................................................
Everyone on this board don't get overly excited. This was dated 2003.
However, I did a quick search on EDGAR under heading Recaf and Dec 27, 2007 Innexus was specific in saying they are using monoclonal antibiotics targeting the receptor for Recaf. What is up with this?